Terms: = Gastric cancer AND uPA AND Prognosis
28 results:
1. Diallyl disulfide inhibits the metastasis of type Ⅱ esophageal‑gastric junction adenocarcinoma cells via NF-κB and PI3K/AKT signaling pathways in vitro.
Yin X; Feng C; Han L; Ma Y; Jiao Y; Wang J; Jia L; Jing F; Gao X; Zhang Y; Zhang J
Oncol Rep; 2018 Feb; 39(2):784-794. PubMed ID: 29207122
[TBL] [Abstract] [Full Text] [Related]
2. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract] [Full Text] [Related]
3. IGFBP3, a transcriptional target of homeobox D10, is correlated with the prognosis of gastric cancer.
Xue M; Fang Y; Sun G; Zhuo W; Zhong J; Qian C; Wang L; Wang L; Si J; Chen S
PLoS One; 2013; 8(12):e81423. PubMed ID: 24386080
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of tumor-related molecular expression in gastric carcinoma.
Zhao ZS; Wang YY; Ye ZY; Tao HQ
Pathol Oncol Res; 2009 Dec; 15(4):589-96. PubMed ID: 19294533
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer.
Wu CY; Wu MS; Chen YJ; Chen HP; Chen CJ; Chang CS; Lin JT
Hepatogastroenterology; 2008; 55(86-87):1890-4. PubMed ID: 19102416
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor.
Hu XW; Duan HF; Gao LH; Pan SY; Li YM; Xi Y; Zhao SR; Yin L; Li JF; Chen HP; Wu CT
Cancer Biol Ther; 2008 May; 7(5):651-9. PubMed ID: 18245952
[TBL] [Abstract] [Full Text] [Related]
7. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers.
Vidal O; Soriano-Izquierdo A; Pera M; Elizalde JI; Palacín A; Castells A; Piqué JM; Volant A; Metges JP
J Gastrointest Surg; 2008 Jun; 12(6):1005-14. PubMed ID: 17972143
[TBL] [Abstract] [Full Text] [Related]
8. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract] [Full Text] [Related]
9. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
Ji F; Chen YL; Jin EY; Wang WL; Yang ZL; Li YM
World J Gastroenterol; 2005 Jun; 11(21):3222-6. PubMed ID: 15929171
[TBL] [Abstract] [Full Text] [Related]
10. Tumour-associated urokinase-type plasminogen activator (upa) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract] [Full Text] [Related]
11. gastric adenocarcinoma: pathomorphology and molecular pathology.
Werner M; Becker KF; Keller G; Höfler H
J Cancer Res Clin Oncol; 2001 Apr; 127(4):207-16. PubMed ID: 11315254
[TBL] [Abstract] [Full Text] [Related]
12. A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.
Noack F; Schmitt M; Bauer J; Helmecke D; Krüger W; Thorban S; Sandherr M; Kuhn W; Graeff H; Harbeck N
Int J Biol Markers; 2000; 15(1):100-4. PubMed ID: 10763150
[TBL] [Abstract] [Full Text] [Related]
13. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Schildberg FW; Heiss MM
Clin Exp Metastasis; 1998 Jan; 16(1):62-73. PubMed ID: 9502078
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Allgayer H; Babic R; Beyer BC; Grützner KU; Tarabichi A; Schildberg FW; Heiss MM
Oncology; 1998; 55(2):152-60. PubMed ID: 9499190
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic factors in gastric cancer.
Allgayer H; Heiss MM; Schildberg FW
Br J Surg; 1997 Dec; 84(12):1651-64. PubMed ID: 9448610
[TBL] [Abstract] [Full Text] [Related]
16. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract] [Full Text] [Related]
17. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Wilhelm Schildberg F; Heiss MM
Cancer; 1997 Jul; 80(2):179-87. PubMed ID: 9217027
[TBL] [Abstract] [Full Text] [Related]
18. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Cancer; 1996 Mar; 77(6):1035-43. PubMed ID: 8635120
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic relevance of urokinase-type plasminogen activator (upa) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
[TBL] [Abstract] [Full Text] [Related]
[Next]
